Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Scholar Rock ...

Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye ...

New studies indicate that weight-loss drugs may lead to serious eye diseases and vision loss in some individuals, prompting ...

Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

Obesity is a worldwide problem that is increasing. It also is associated with ocular problems. A recent study found that in ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

Overview - As demand for GLP-1 drugs continues to skyrocket, federal and state agencies are turning their attention to the GLP-1 ...

The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an ...

Aardvark Therapeutics (AARD) announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity ...